Clinical Trial Update: Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA) [Phase 2]

View source ↗

Summary

Phase 2 dose-response trial assessing the effect of the aquaretic tolvaptan on the nitric oxide system in nephropathy; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephropathy

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Sponsor: Regional Hospital Holstebro | Conditions: Nephropathy | Phase 2 | Status: COMPLETED